Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 8

Recent Approaches against SARS-COV-2: The Ongoing Outbreak of Coronavirus Disease 2019 (COVID-19)

Manas Chakraborty1, Indranil Chatterjee2*, Suman Kumar Nath2, Nilayan Guha3, Raksha Ray4 and Roushan Bhaskar4

1Professor, Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and Allied Health Sciences, Howrah, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
3Assistant Professor, Bharat Technology, Howrah, West Bengal, India
4B. Pharm, P.G Institute of Medical Sciences, Chandrakona Town, Paschim Midnapore, West Bengal, India

*Corresponding Author: Indranil Chatterjee, Assistant Professor, Department of Microbiology, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: June 02, 2020; Published: July 11, 2020

Reprints View PDF Related Articles

×

Abstract

 Novel extreme intense respiratory condition coronavirus 2 (SARS-CoV-2) lies behind the continuous episode of coronavirus malady 2019 (COVID-19). There is a developing comprehension of SARS-CoV-2 in virology, the study of disease transmission, and clinical administration systems. Be that as it may, no enemy of SARS-CoV-2 medication or antibody has been authoritatively affirmed because of the nonattendance of satisfactory proof. Researchers are dashing to build up a treatment for COVID-19. Late investigations have uncovered numerous alluring remedial choices, regardless of whether some of them stay to be additionally affirmed in thorough preclinical models and clinical preliminaries. In this minireview, we mean to sum up the refreshed potential methodologies against SARS-CoV-2. We stress that further endeavors are justified to build up the most secure and best methodology.

Keywords: COVID-19; SARS-CoV-2; Antiviral Drugs; Treatment; Vaccines

×

References

  1. Guan WJ., et al.“Clinical characteristics ofcoronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
  2. World Health Organization. Coronavirus disease 2019 (COVID-19)situation report—53 (2020).
  3. Zhu N., et al. “A novelcoronavirus from patients with pneumonia in China, 2019”. The New England Journal of Medicine382 (2020): 727-733.
  4. Tian X., et al. “Potent binding of 2019 novel coronavirus spike protein by aSARS coronavirus-specific human monoclonal antibody”. Emerging Microbes and Infections 9 (2020): 382-385.
  5. Li Q., et al. “Early transmission dynamics in Wuhan, China, ofnovel coronavirus-infected pneumonia”. The New England Journal of Medicine (2020).
  6. Zhao YZZ., et al. “Single-cell RNA expressionprofiling of ACE2, the putative receptor of Wuhan 2019-nCov”.BioRxiv (2020).
  7. National Health Commission of the People’s Republic of China. Notice on printing and distributing the diagnosis and treatment plan ofpneumonia with new coronavirus infection (trial version 7) (2020).
  8. Walls AC., et al. “Structure, function, and antigenicity of the SARSCoV-2 spike glycoprotein”. Cell (2020).
  9. Zhou P., et al. “A pneumonia outbreakassociated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
  10. Wan Y., et al. “Receptor recognition by novel coronavirus from Wuhan: an analysisbased on decade-long structural studies of SARS”. Journal of Virology (2020).
  11. Zheng M., et al. “Novel antibody epitopesdominate the antigenicity of spike glycoprotein in SARS-CoV-2 comparedto SARS-CoV”. Cellular and Molecular Immunology (2020).
  12. Zhang H., et al. “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2receptor: molecular mechanisms and potential therapeutic target”. IntensiveCare Medicine (2020).
  13. Kruse RL. “Therapeutic strategies in an outbreak scenario to treatthe novel coronavirus originating in Wuhan, China”. F1000Research 9 (2020): 72.
  14. Hoffmann M., et al. “SARS-CoV-2 cell entry dependson ACE2 and TMPRSS2 and is blocked by a clinically proven proteaseinhibitor”. Cell (2020).
  15. Xia S., et al. “Fusion mechanism of 2019-nCoV andfusion inhibitors targeting HR1 domain in spike protein”. Cellular and Molecular Immunology (2020).
  16. Inoue Y., et al. “Clathrin-dependent entry of severe acute respiratorysyndrome coronavirus into target cells expressing ACE2 with the cytoplasmictail deleted”. Journal of Virology 81 (2007): 8722-8729.
  17. Wang H., et al. “SARScoronavirus entry into host cells through a novel clathrin- and caveolaeindependentendocytic pathway”. Cell Research 18 (2008): 290-301.
  18. Neveu G., et al. “AP-2-associated protein kinase 1 and cyclin G-associated kinaseregulate hepatitis C virus entry and are potential drug targets”. Journal of Virology89 (2015): 4387- 4404.
  19. Richardson P., et al. “Baricitinib as potential treatment for 2019-nCoVacute respiratory disease”. Lancet 395 (2020): e30- e31.
  20. Blaising J., et al. “Arbidol as a broad-spectrumantiviral: an update”. Antiviral Research 107 (2014): 84-94.
  21. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recentlyemerged novel coronavirus (2019-nCoV) in vitro”. Cell Research30 (2020): 269-271.
  22. Gao J., et al. “Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment ofCOVID-19 associated pneumonia in clinical studies”. Bioscience Trends (2020).
  23. Yao X., et al. “In vitroantiviral activity and projection of optimized dosing design of hydroxychloroquinefor the treatment of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2)”. Clinical Infection Disease (2020).
  24. Savarino A., et al. “Effects ofchloroquine on viral infections: an old drug against today’s diseases?”Lancet Infection Disease 3 (2003): 722-727.
  25. Martinez MA. “Compounds with therapeuticpotential against novel respiratory 2019 coronavirus”. Antimicrobe AgentsChemotherapy (2020).
  26. Gordon CJ., et al. “The antiviral compound remdesivir potentlyinhibits RNA-dependent RNA polymerase from Middle East respiratorysyndrome coronavirus”. Journal of Biological Chemistry (2020).
  27. Holshue ML., et al. “First case of 2019 novel coronavirus in the United States”. The New England Journal of Medicine 382 (2020): 929-936.
  28. Li G and De Clercq E. “Therapeutic options for the 2019 novel coronavirus (2019-nCoV)”. Nature Review on Drug Discovery19 (2020): 149-150.
  29. Morse JS., et al. “Learning from the past: possibleurgent prevention and treatment options for severe acute respiratoryinfections caused by 2019-nCoV”. Chembiochemistry 21 (2020): 730-738.
  30. Li YZJ., et al. “Therapeutic drugs targeting 2019-nCoV main protease by high throughputscreening”. BioRxiv(2020).
  31. Nguyen TM., et al. “Virus against virus: a potentialtreatment for 2019-nCov (SARS-CoV-2) and other RNA viruses”. Cell Research30 (2020): 189-190.
  32. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirusin Wuhan, China”. Lancet 395 (2020): 497-506.
  33. Zhou YF., et al. “Aberrant pathogenic GM-CSFT cells and inflammatoryCD14 CD16monocytes in severe pulmonary syndrome patients of anew coronavirus”. BioRxiv(2020).
  34. Russell CD., et al. “Clinical evidence does not supportcorticosteroid treatment for 2019-nCoV lung injury”. Lancet 395 (2020): 473-475.
  35. Zhou W., et al. “Potential benefits of precise corticosteroids therapy for severe2019-nCoV pneumonia”. Signal Transduction and Targeted Therapy 5 (2020): 18.
  36. Fu Y., et al. “UnderstandingSARS-CoV-2-mediated inflammatory responses: from mechanisms to potentialtherapeutic tools”. VirologicaSinica (2020).
  37. Chen L., et al. “Convalescentplasma as a potential therapy for COVID-19”. Lancet Infection Disease (2020).
  38. Garraud O., et al. “Plasma therapy against infectious pathogens, as of yesterday,today and tomorrow”. Transfusion Clinique et Biologique23 (2016): 39-44.
  39. Marano G., et al. “Convalescent plasma: new evidence for an old therapeutictool?”Blood Transfusion 14 (2016): 152-157.
  40. National Health Commission of the People’s Republic of China. Noticeon printing and distributing the convalescent plasma treatment for novelcoronavirus pneumonia (trial version 2) (2020).
  41. Lu S. “Timely development of vaccines against SARS-CoV-2”. Emerging Microbes and Infections 9 (2020): 542-544.
  42. Wrapp D., et al. “Cryo-EM structure of the 2019-nCoV spikein the prefusion conformation”. Science 367 (2020): 1260-1263.
  43. Lucchese G. “Epitopes for a 2019-nCoVvaccine”. Cellular and Molecular Immunology (2020).
  44. Ahmed SF., et al. “Preliminary identification ofpotential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2)based on SARS-CoV immunological studies”. Viruses 12 (2020): E254.
  45. Pang J., et al. “Potential rapid diagnostics,vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematicreview”. Journal of Clinical Medicine (2020).
  46. CEPI to fund three programmes to develop vaccines againstthe novel coronavirus, ncov-2019 (2020).
  47. Lu H. “Drug treatment options for the2019-new coronavirus (2019-nCoV)”. Bioscience Trends (2020).
  48. Ren JL., et al. “Traditional Chinese medicine forCOVID-19 treatment”. Pharmacology Research 155 (2020): 104743.
  49. Ding Y., et al. “The Chinese prescription lianhuaqingwencapsule exerts anti-influenza activity through the inhibition of viralpropagation and impacts immune function”. BMC Complementary and Alternative Medicine 17 (2017): 130.
  50. Ji S., et al. “Uniquesynergistic antiviral effects of ShufengJiedu Capsule and oseltamivir ininfluenza A viral-induced acute exacerbation of chronic obstructivepulmonary disease”. Biomed Pharmacotherapy 121 (2020): 109652.
  51. Wang Z., et al. “Clinical characteristics and therapeutic procedure for four cases with2019 novel coronavirus pneumonia receiving combined Chinese andWestern medicine treatment”. Bioscience Trends(2020).
×

Citation

Citation: Indranil Chatterjee., et al. “Recent Approaches against SARS-COV-2: The Ongoing Outbreak of Coronavirus Disease 2019 (COVID-19)". Acta Scientific Microbiology 3.8 (2020): 26-32.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.